Rituximab maintenance treatment of relapsed/resistant follicular non-hodgkin's lymphoma: Long-term outcome of the EORTC 20981 phase III randomized intergroup study

Journal of Clinical Oncology

Volumn 28, Issue 17, 2010, Pages 2853-2858

  Van Oers, Marinus H J ^a   Van Glabbeke, Martine ^a   Giurgea, Livia ^a   Klasa, Richard ^a   Marcus, Robert E ^a   Wolf, Max ^a   Kimby, Eva ^a   Vant Veer, Mars ^a   Vranovsky, Andrej ^a   Holte, Harald ^a   Hagenbeek, Anton ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; MONOCLONAL ANTIBODY;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; DRUG EFFICACY; DRUG WITHDRAWAL; FOLLICULAR LYMPHOMA; HEART VENTRICLE ARRHYTHMIA; HUMAN; INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; MULTICENTER STUDY; REMISSION; SURVIVAL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; HUMANS; LYMPHOMA, FOLLICULAR; PREDNISONE; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 77956413908     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.5827     Document Type: Article

References (17)

1. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005 (Pubitemid 41742196)
2. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005 (Pubitemid 40223656)
3. Salles G, Mounier N, de Guibert S, et al: Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Results of the GELAGOELAMS FL2000 study. Blood 112:4824-4831, 2008
4. Herold M, Haas A, Srock S, et al: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J Clin Oncol 25:1986-1992, 2007
5. van Oers MH: Rituximab maintenance therapy: A step forward in follicular lymphoma. Haematologica 92:826-833, 2007
6. van Oers MH, Klasa R, Marcus RE, et al: Rituximab maintenance improves clinical outcome of relapsed/ resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 108:3295-3301, 2006 (Pubitemid 44794222)
7. Hainsworth JD, Litchy S, Shaffer DW, et al: Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - A randomized phase II trial of the Minnie Pearl Cancer Res Network. J Clin Oncol 23:1088-1095, 2005 (Pubitemid 46202263)
8. Ghielmini M, Schmitz SF, Cogliatti SB, et al: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 103:4416-4423, 2004 (Pubitemid 38745964)
9. Hochster H, Weller E, Gascoyne RD, et al: Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG1496 Study. J Clin Oncol 27:1607-1614, 2009
10. Forstpointner R, Dreyling M, Repp R, et al: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104:3064-3071, 2004 (Pubitemid 39517009)
11. Vidal L, Gafter-Gvili A, Leibovici L, et al: Rituximab maintenance for the treatment of patients with follicular lymphoma: Systematic review and metaanalysis of randomized trials. J Natl Cancer Inst 101:248-255, 2009
12. Gordan LN, Grow WB, Pusateri A, et al: Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 23:1096-1102, 2005 (Pubitemid 46202264)
13. Kimby E: Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31:456-473, 2005
14. Ghielmini M, Rufibach K, Salles G, et al: Single agent rituximab in patients with follicular or mantle cell lymphoma: Clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: A study of the Swiss Group for Clinical Cancer Res (SAKK). Ann Oncol 16:1675-1682, 2005 (Pubitemid 41510143)
15. Fogarty GB, Bayne M, Bedford P, et al: Three cases of activation of cutaneous squamous-cell carcinoma during treatment with prolonged administration of rituximab. Clin Oncol (R Coll Radiol) 18:155-156, 2006 (Pubitemid 43169149)
16. Carson KR, Focosi D, Major EO, et al: Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: A review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 10:816-824, 2009
17. Hitz F, Bassi S, Taverna C, et al: First results of long-term rituximab maintenance treatment in follicular lymphoma: Safety analysis of the randomized phase III trial SAKK 35/03. 14th Congress of the European Hematology Association, Berlin, Germany, June 4-7, 2009 (abstr 0413)